Altigen shares fall 16.01% to 168,400 won after U.S. drug price negotiation rule
Key Facts
Altigen shares closed at 168,400 won in the November 9, 2026 session, down 16.01%, or 32,100 won, amid the U.S. announcement of a final rule for its drug price negotiation program. EDaily reported that the decline coincided with the completion of U.S. rules governing negotiations, raising investor concerns about drug formulations that could fall within the program. The U.S. Centers for Medicare & Medicaid Services issued the rule on November 5, 2026, formalizing Medicare negotiation policies for the 2029 implementation year and beyond. The move establishes a regulatory framework that could affect drug products with different forms and routes of administration, but its scope is limited by conditions related to ingredients and the holder of the drug application. The commercial link for Altigen stems from market concerns about the rule's implications for the Keytruda Qlex formulation, rather than a determination that the rule will have a direct financial impact on the company.
The rule allows the Centers for Medicare & Medicaid Services to identify a potentially qualifying drug for negotiation using all its forms and strengths, if specified conditions are met. This includes products that share an active ingredient and have a single holder of a drug application of the NDA or BLA type, together with an additional ingredient that enables an alternative route of administration. The policy therefore does not mean that every drug converted from intravenous to subcutaneous injection will automatically be subject to negotiations. The focus is on grouping the forms and dosages of a particular qualifying drug according to the relationship between its ingredients and regulatory applications, not on a change in the route of administration alone. This distinction matters in assessing investor concerns about new formulations, because it ties the rule's application to the product's composition and the application holder.
The Centers for Medicare & Medicaid Services said the policy is intended to address program integrity risks, including the possibility that a new formulation could provide an alternative route of administration while the original product and the new formulation remain outside a single grouping when the qualifying drug is identified. The agency said the aim is to comply with the statutory requirement to aggregate forms and dosages for a qualifying drug. It gave the example of a product containing an active ingredient and hyaluronidase, explaining that a product combining the two would be identified as part of the same potentially qualifying drug. This means that an additional ingredient allowing an alternative route of administration may factor into the assessment of the relationship between formulations, subject to the conditions set out in the rule. The official text does not mention Altigen or its technology by name; the commercial link and investor concerns appeared in press coverage.
The concerns come as Keytruda Qlex generated sales of 830 million dollars in the third quarter of 2026, according to Merck's results. Combined sales of Keytruda and Keytruda Qlex reached about 8.601 billion dollars in the same period, up 6% from the third quarter of 2025. This growth puts sales of the new formulation within strong commercial performance for the two products combined, while the rule's potential pricing impact remains tied to the program's conditions and upcoming cycle. The figures show the scale of commercial activity around the product, but do not prove that the rule will reduce its sales or Altigen's profits. The regulatory question centers on whether formulations with shared ingredients meet the criteria for identifying a qualifying drug for negotiation.
The regulations take effect on December 5, 2026, and apply to the negotiation program starting with the 2029 implementation year, and to Medicare Part D coverage from January 1, 2029. Negotiations for the fourth cycle are scheduled for 2027, with agreed prices taking effect on January 1, 2029, for drugs that reach an agreement. As a next step, the Centers for Medicare & Medicaid Services said it will select up to 20 additional drugs eligible for negotiation in the fourth cycle by February 1, 2027. The list may include drugs covered under Part D or drugs paid for through Part B, and the agency may also select drugs for renegotiation. Those selections will determine which drugs enter the next cycle before prices begin to take effect in 2029.